TD Securities Lowers Cipher Pharmaceuticals Inc (CPH) Price Target to C$5.00
Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) had its price target cut by investment analysts at TD Securities from C$6.50 to C$5.00 in a report released on Tuesday. The firm currently has a “hold” rating on the stock. TD Securities’ price objective would suggest a potential upside of 11.11% from the stock’s previous close.
Separately, Bloom Burton lowered shares of Cipher Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 14th.
Shares of Cipher Pharmaceuticals (TSE CPH) traded down C$0.14 during midday trading on Tuesday, reaching C$4.50. 12,360 shares of the company traded hands, compared to its average volume of 10,046. Cipher Pharmaceuticals has a fifty-two week low of C$3.50 and a fifty-two week high of C$5.75.
ILLEGAL ACTIVITY WARNING: “TD Securities Lowers Cipher Pharmaceuticals Inc (CPH) Price Target to C$5.00” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/11/07/td-securities-lowers-cipher-pharmaceuticals-inc-cph-price-target-to-c5-00.html.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc, together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in South America, Canada, and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.
Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.